Zobrazeno 1 - 10
of 278
pro vyhledávání: '"Yingyi Wang"'
Autor:
Lingzhi Hong, Sonia Patel, Leylah M. Drusbosky, Yuanyuan Xiong, Rongrong Chen, Ruixuan Geng, Simon Heeke, Monique Nilsson, Jia Wu, John V. Heymach, Yingyi Wang, Jianjun Zhang, Xiuning Le
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract ERBB2 (HER2) represents a newly recognized actionable oncogenic driver in non-small cell lung cancer (NSCLC), with approved targeted therapy available. Understanding the landscape of ERBB2 alterations and co-occurring mutations is essential
Externí odkaz:
https://doaj.org/article/7d1f2cdad9384d7bb4c05d844e0f4351
Autor:
Kejie Guan, Yinxiao Li, Lin Liu, Fuqin Sun, Yingyi Wang, Zhuo Zheng, Weifan Zhou, Cheng Zhang, Zhengyang Cai, Xiaowei Wang, Simin Feng, Ting Zhang
Publikováno v:
Microsystems & Nanoengineering, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Owing to the controllable growth and large-area synthesis for high-density integration, interest in employing atomically thin two-dimensional (2D) transition-metal dichalcogenides (TMDCs) for synaptic transistors is increasing. In particular
Externí odkaz:
https://doaj.org/article/f19d16b1bf0240dab8bf57c9b952aa6c
Autor:
Shuling Shi, Bingyan Li, Pengcheng Zhou, Linhui Chen, Huizhen Li, Yingyi Wang, Xiaoyu Deng, Qianqian Dang, Jingjing Wu, Boya Zha, Peihong Li, Yingjuan Zheng, Daoke Yang
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Objective To analyze the efficacy and adverse effects of anti‐PD‐1 immune checkpoint inhibitors aimed at nasopharyngeal carcinoma (NPC). Methods During the first stage of the study, using 40 patients with stage III/IVa NPC treated with a
Externí odkaz:
https://doaj.org/article/eb1bcefdabd34e0c98f940afcf24f7a5
Publikováno v:
Heliyon, Vol 10, Iss 12, Pp e32770- (2024)
Objective: To identify the gut bacteria associated with chemotherapeutic outcomes, t characterized the gut microbiota in patients with esophageal squamous cell carcinoma (ESCC) in this prospective study. Design: Thirty-one patients with ESCC were enr
Externí odkaz:
https://doaj.org/article/011e641db53a4e8cbd185831ced87b57
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Ulcerative colitis (UC), a subtype of inflammatory bowel disease, manifests with symptoms such as abdominal pain, diarrhea, and mucopurulent, bloody stools. The pathogenesis of UC is not fully understood. At present, the incidence of UC has increased
Externí odkaz:
https://doaj.org/article/bded65e29d3d46fb9f282326587e6dee
Autor:
Shuling Shi, Yingyi Wang, Jingjing Wu, Boya Zha, Peihong Li, Yukun Liu, Yuchuan Yang, Jinglin Kong, Shibo Gao, Haiyang Cui, Linkuan Huangfu, Xiaocong Sun, Zhikai Li, Tiansong Liang, Yingjuan Zheng, Daoke Yang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo investigate the correlation between programmed death ligand 1(PD-L1), tumor mutation burden (TMB) and the short-term efficacy and clinical characteristics of anti-PD-1 immune checkpoint inhibitor combination chemotherapy in NSCLC patients
Externí odkaz:
https://doaj.org/article/94e0b2179c03445b9be297581be8c2c8
Publikováno v:
Antioxidants, Vol 13, Iss 8, p 1012 (2024)
Oxidative stress (OS) is a key factor in the generation of various pathophysiological conditions. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) is a major transcriptional regulator of antioxidant reactions. Heme oxygenase-1 (HO-1), a gen
Externí odkaz:
https://doaj.org/article/2fdd2881b1ac4baca78625fc544e8dc4
Autor:
Bao Jin, Yuxin Wang, Baoluhe Zhang, Haifeng Xu, Xin Lu, Xinting Sang, Wenze Wang, Yilei Mao, Pengxiao Chen, Shun Wang, Zhirong Qian, Yingyi Wang, Shunda Du
Publikováno v:
Cancer Medicine, Vol 12, Iss 20, Pp 20470-20481 (2023)
Abstract Background Therapeutic approaches for extrahepatic cholangiocarcinoma (EHCC) are limited, due to insufficient understanding to biomarkers related to prognosis and drug response. Here, we comprehensively assess the molecular characterization
Externí odkaz:
https://doaj.org/article/c9864a70974149a49598318863429d1f
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 10, Pp 765-778 (2023)
Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall surv
Externí odkaz:
https://doaj.org/article/dbf6b10f470643258c7a8efcf89f7ed2
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background There are no standard third-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC). Trametinib in combination with hydroxychloroquine (HCQ) or CDK4/6 inhibitors for pancreatic adenocarcinoma showed promisin
Externí odkaz:
https://doaj.org/article/1841ba58b92c4afb816a8e4746613cf5